Cara Therapeutics   Report issue

For profit Phase 1 Phase 3
Founded: Shelton CT United States (2004)

Organization Overview

First Clinical Trial
2009
NCT00877799
First Marketed Drug
2021
difelikefalin (Korsuva)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

CARA THERAP | Cara Therapeutics | Cara Therapeutics, Inc.

Active Ingredients

Marketed Drugs (1)

difelikefalin (Korsuva) (2021)

Drugs in Phase 3 Trials (1)

difelikefalin (Korsuva) (19 trials)

Drugs in Phase 1 Trials (1)

moxifloxacin (avelox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 2)

Cholangitis (Phase 2)

Collagen Diseases (Phase 2)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Joint Diseases (Phase 2)

Kidney Diseases (Phase 2)

Kidney Failure, Chronic (Phase 1)

Musculoskeletal Diseases (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Hip (Phase 2)

Osteoarthritis, Knee (Phase 2)

Pain, Postoperative (Phase 2)

Pruritus (Phase 3)

Renal Insufficiency, Chronic (Phase 2)

Rheumatic Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial APIs: 2